Connor, Clark & Lunn Investment Management Ltd. Fate Therapeutics Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$9.86 - $23.83 $799,133 - $1.93 Million	81,048 Added 27.03%	380,862 $3.84 Million
Q3 2022 Nov 10, 2022	BUY	$21.04 - $36.06 $5.17 Million - $8.86 Million	245,639 Added 453.42%	299,814 $6.72 Million
Q2 2022 Aug 05, 2022	BUY	$17.78 - $42.39 $826,947 - $1.97 Million	46,510 Added 606.78%	54,175 $1.34 Million
Q1 2022 May 12, 2022	BUY	$29.67 - $60.28 $227,420 - $462,046	7,665 New	7,665 $297,000
Q3 2021 Nov 12, 2021	SELL	$59.27 - $95.73 $4.22 Million - $6.81 Million	-71,184 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $470,682 - $647,547	6,999 Added 10.9%	71,184 $6.18 Million
Q1 2021 May 13, 2021	BUY	$72.16 - $117.4 $2.27 Million - $3.69 Million	31,410 Added 95.84%	64,185 $5.29 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $973,999 - $2.58 Million	25,571 Added 354.96%	32,775 $2.98 Million
Q3 2020 Nov 12, 2020	BUY	$30.41 - $40.5 $219,073 - $291,762	7,204 New	7,204 $288,000
Q1 2018 May 14, 2018	SELL	$6.3 - $13.77 $182,070 - $397,953	-28,900 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$3.94 - $6.64 $142,234 - $239,704	-36,100 Reduced 55.54%	28,900 $177,000
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $3,900 - $6,464	1,500 Added 2.36%	65,000 $257,000
Q2 2017 Aug 14, 2017	BUY	N/A	63,500	63,500 $206,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

Redmile Group, LLC San Francisco, CA

13.2M
Shares

$21.9 Million
3.01% of portfolio
Vanguard Group Inc Valley Forge, PA

10.4M
Shares

$17.3 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$16.8 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

5.57M
Shares

$9.25 Million
0.72% of portfolio
State Street Corp Boston, MA

5.25M
Shares

$8.72 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account